Skip to content
Advertisement

CEO Werner Baumann, right, and Chairman of the Supervisory Board Werner Wenning, left, shake hands during the annual general meeting of the Bayer stock company in Bonn, Germany, Friday, April 26, 2019. Following the record acquisition of U.S. biotech and seed company Monsanto, Bayer's agricultural business has become a risk for the German chemical company. Bayer is facing enormous cost if the U.S. court will find Monsanto's glyphosate to be causing cancer. Since the take-over of Monsanto in June 2018, Bayer lost around half of its value in market capitalization. (AP Photo/Martin Meissner)

CEO Werner Baumann, right, and Chairman of the Supervisory Board Werner Wenning, left, shake hands during the annual general meeting of the Bayer stock company in Bonn, Germany, Friday, April 26, 2019. Following the record acquisition of U.S. biotech and seed company Monsanto, Bayer's agricultural business has become a risk for the German chemical company. Bayer is facing enormous cost if the U.S. court will find Monsanto's glyphosate to be causing cancer. Since the take-over of Monsanto in June 2018, Bayer lost around half of its value in market capitalization. (AP Photo/Martin Meissner)

Featured Photo Galleries